Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05136664 | Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects | PHASE3 | COMPLETED | 262 | — | — | Feb 10, 2022 | Nov 18, 2025 | Apr 13, 2026 | 28 | China |
Measured in milliequivalents per litre (mEq/L)
Measured in mEq/L
| Arm | Type | Description |
|---|---|---|
| Part A: Patiromer | EXPERIMENTAL | Part A: 4-week, single-arm patiromer treatment phase (4 weeks) |
| Part B: Placebo | PLACEBO_COMPARATOR | Part B: 8-week randomized, parallel group, placebo-controlled withdrawal phase |
| Part B: Patiromer | EXPERIMENTAL | Part B: 8-week randomized, parallel group, placebo-controlled withdrawal phase |
| Name | Type | Description |
|---|---|---|
| Patiromer Powder for Oral Suspension (Part A) | DRUG | Participants initiate patiromer at an oral dose of 1 packet/day (8.4g/day as powder for suspension). The dose is adjusted ate the following visit based on local serum potassium (sK+) levels. The content of each packet should be mixed with water, apple or cranberry juice before administration. |
| Placebo (Part B) | DRUG | Placebo is provided in packets, each containing 6 g of placebo as powder for suspension. Participants will take 1 packet per day, by mixing its content with water, apple or cranberry juice. |
| Patiromer Powder for Orals Suspension (Part B) | DRUG | Participants will continue to receive the same number of packets established during Part A, but dose may be up- or down titrated depending on sK+ levels. The content of each packet should be mixed with water, apple or cranberry juice before administration. |
Inclusion Criteria: * \- Chinese subjects at least 18 years of age. * \- Chronic Kidney Disease (CKD) stage 3 and 4. * \- Mean of 2 measurement of serum potassium higher than 5.0 and lower than 6.5 mEq/L at baseline. * \- Subjects on any stable dose of at least 1 RAASi medication for at least 28 da...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 3 | PHASE3 | Zirconium Cyclosilicate Reduced Dose Level, Zirconium Cyclosilicate Dose Level 1, Zirconium Cyclosilicate Dose During 28 Day Maintenance Phase |